admin
India
healthysoch
New Delhi, February 27, 2021 :
The WHO recommendation on the composition of influenza virus vaccines for use in the northern hemisphere 2021-2022 was announced in the WHO Information Meeting and Round-table Discussion with manufacturers and regulatory agencies today, 26 February 2021.
It followed the 7-day virtual Consultation Meeting with Advisers from WHO Collaboration Centres (CCs) and WHO Essential Regulatory Laboratories (ERLs) based on year-round surveillance by the WHO Global Influenza Surveillance and Response System (GISRS).
It is recommended that quadrivalent vaccines for use in the 2021-2022 northern hemisphere influenza season contain the following:
Egg-based Vaccines
- an A/Victoria/2570/2019 (H1N1)pdm09-like virus;
- an A/Cambodia/e0826360/2020 (H3N2)-like virus;
- a B/Washington/02/2019 (B/Victoria lineage)-like virus; and
- a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
Cell- or recombinant-based Vaccines
- an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
- an A/Cambodia/e0826360/2020 (H3N2)-like virus;
- a B/Washington/02/2019 (B/Victoria lineage)-like virus; and
- a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
It is recommended that trivalent influenza vaccines for use in the 2021-2022 northern hemisphere influenza season contain the following:
Egg-based Vaccines
- an A/Victoria/2570/2019 (H1N1)pdm09-like virus;
- an A/Cambodia/e0826360/2020 (H3N2)-like virus; and
- a B/Washington/02/2019 (B/Victoria lineage)-like virus.
Cell- or recombinant-based Vaccines
- an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
- an A/Cambodia/e0826360/2020 (H3N2)-like virus; and
- a B/Washington/02/2019 (B/Victoria lineage)-like virus.
The full technical report can be found at:
https://www.who.int/influenza/
healthysoch
HealthySoch
